U.S. National Institutes of Health’s candidate AIDS vaccine trial suffers major setback

Just a few months ago, news of a potential HIV vaccine generated considerable interest in the medical community, including promising advances and new drugs being developed,media BGR reported. Unfortunately, efforts to rid the world of HIV have suffered a major setback, as an ongoing HIV vaccine trial at the National Institutes of Health (NIH) has proved to be largely ineffective.

U.S. National Institutes of Health's candidate AIDS vaccine trial suffers major setback

The vaccine candidate was tested in more than 5,000 people in South Africa, the BBC reported. The vaccine was specifically designed to fight common strains of the virus in the region, and despite extensive research on the drug, the HIV infection rate in the treatment group was actually higher than in the placebo group.

“The HIV vaccine is critical to ending the global pandemic, and we hope that this candidate vaccine will work,” said Dr. Anthony Fauci of the National Institutes of Health. Unfortunately, this is not the case. Research is continuing on other methods of safe and effective HIV vaccine, and I still believe it can be achieved. “

According to the researchers who tested, 123 infections were recorded in people receiving a placebo injection, while 129 infections were confirmed in those receiving a candidate vaccine. Clearly, this is bad news, and the National Institutes of Health has canceled further tests because the vaccine doesn’t seem to work.

Although the vaccine’s failure disappointed researchers, it was not the end. Other HIV vaccine candidates are still in stages of development and testing, and health experts still believe a viable vaccine against the disease could be ready in just a few years.